Vitalant Research Institute, Denver, Colorado, USA.
ClinImmune Labs/Department of Medicine, University of Colorado, Aurora, Colorado, USA.
Transfusion. 2022 May;62(5):954-960. doi: 10.1111/trf.16878. Epub 2022 Apr 11.
A 2-year-old, 10.8 kg male pediatric patient with X-linked chronic granulomatous disease (CGD) with McLeod syndrome (MLS) was scheduled for a hematopoietic stem cell transplant (HSCT). Identification of allogenic red blood cells (RBC) for post-transplant support was unsuccessful prompting the development of a customized method to collect and freeze rare autologous pediatric cells.
A protocol was developed for the collection of small volume pediatric whole blood (WB) via peripheral venipuncture with collection into 10 ml syringes containing anticoagulants. Additionally, a closed system RBC glycerolization and deglycerolization instrument was adapted to process small volume, non-leukoreduced WB. Both collection and WB processes were validated. In total 4 approximately 100 ml autologous units were collected and frozen. Two units were thawed, deglycerolized, and used for clinical transfusion support. To appreciate processing impacts on RBC rigidity, ektacytometry was performed on pre-processed and post-deglycerolization samples.
Free hemoglobin (HGB) of validation units after thawing/deglycerolization was <150 mg/dL with an average red cell recovery of 85%. These units also showed little difference between pre-and post-processing Lorrca deformability curves or membrane rigidity. Two pediatric units were thawed and deglycerolized for transfusion. Free HGB was 70 mg/dL and 50 mg/dL post-thaw, and these RBCs had a slight decrease in deformability and increased membrane rigidity.
Customized WB collection, glycerolization, freezing, and deglycerolization processes were developed to successfully support a pediatric patient with CGD and MLS after autologous HSCT. Both pediatric units showed increased membrane rigidity post-deglycerolization which may be a consequence of the CGD and MLS genetic background.
一名 2 岁、10.8 公斤的男性儿科患者患有 X 连锁慢性肉芽肿病(CGD)伴 McLeod 综合征(MLS),拟行造血干细胞移植(HSCT)。由于未能成功鉴定出用于移植后支持的同种异体红细胞(RBC),因此开发了一种定制方法来收集和冷冻罕见的自体儿科细胞。
制定了一项方案,通过外周静脉穿刺采集小体积儿科全血(WB),并将其收集到含有抗凝剂的 10 毫升注射器中。此外,还对小型非白细胞减少 WB 的 RBC 甘油化和去甘油化仪器进行了改造。对采集和 WB 过程进行了验证。共采集和冷冻了 4 个约 100ml 的自体单位。解冻了 2 个单位,去甘油化后用于临床输血支持。为了评估处理对 RBC 刚性的影响,对预处理和去甘油化后的样本进行了 ektacytometry 检测。
解冻/去甘油化后验证单位的游离血红蛋白(HGB)<150mg/dL,红细胞回收率平均为 85%。这些单位在处理前后的 Lorrca 变形性曲线或膜刚性方面也没有明显差异。2 个儿科单位解冻并去甘油化用于输血。解冻后游离 HGB 分别为 70mg/dL 和 50mg/dL,这些 RBC 的变形性略有下降,膜刚性增加。
定制的 WB 采集、甘油化、冷冻和解甘油化过程被开发用于成功支持 CGD 和 MLS 后进行自体 HSCT 的儿科患者。两个儿科单位在去甘油化后都显示出膜刚性增加,这可能是 CGD 和 MLS 遗传背景的结果。